Toshihiro Miyamoto
Experienced in Scleroderma

Toshihiro Miyamoto

Kanazawa, JP 
Experienced in Scleroderma
Kanazawa, JP 
OverviewLocationsClinical Research

Overview

Toshihiro Miyamoto practices in Kanazawa, Japan. Miyamoto is rated as an Experienced expert by MediFind in the treatment of Scleroderma. Their top areas of expertise are Leukemia, Acute Myeloid Leukemia (AML), Adult T-Cell Leukemia, Graft Versus Host Disease (GvHD), and Bone Marrow Transplant.

Their clinical research consists of co-authoring 289 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles in the study of Scleroderma.

Locations

Kanazawa, Japan
Other Locations
Fukuoka, Japan
Higashi, 8128582, Japan
Hamamatsu, Japan
Japan
Chiba, 2778561, Japan
Nishi, Japan
Tokyo, 1138656, Japan
Kashiwa, 2778561, Japan
Gifu-shi, 5061205, Japan
Hiroshima, 7348553, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 Versus Treatment Choice (TC) in Adults With Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for Intensive Remission Induction Chemotherapy
A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 Versus Treatment Choice (TC) in Adults With Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for Intensive Remission Induction Chemotherapy
Enrollment Status: Completed
Publish Date: August 27, 2024
Intervention Type: Drug
Study Phase: Phase 3

289 Total Publications

Decreased factor XIII activity and haptoglobin may be markers of enhanced-fibrinolytic-type disseminated intravascular coagulation status: Case report.
Decreased factor XIII activity and haptoglobin may be markers of enhanced-fibrinolytic-type disseminated intravascular coagulation status: Case report.
Journal: Medicine
Published: July 29, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Miyamoto's expertise for a condition
ConditionClose
View All 12 Advanced Conditions
View All 46 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile